Taking on New Territory: A Conversation with Biocut Systems’ Vice President of Innovation

By: Alexandria Mason
February 3, 2021

It all started with a die.

The same technology that cuts shoe leather and greeting cards is at the core of Biocut Systems’ success in the regenerative medicine industry.

Jared Koch, VP of Product Innovation

“An early adopter inside of the regenerative medicine market space had come to us looking for a unique application to cut skin grafts,” said Vice President of Innovation Jared Koch. “We took that on and in taking on that challenge, they then needed the pressing machinery that would help them out in processing.”

Those presses, Koch described, are a prime example of Biocut’s evolution in inventory over the years. Biocut started down the path of developing the die in parallel to the early pressing machinery. And although by today’s standards it may be seen as “crude,” said Koch, that pressing machinery was built around solid engineering technology.

“The presses went from a single product line to a whole matrix of presses that fit into different size constraints and different processing needs for our customers. From there, we continued to evolve those products by focusing on industrial design, ease of cleaning, improving the product ergonomics and really ease of use,” said Koch. “We focused on improving those products’ reliability and then also reducing setup time. Those things are all valuable to our customers because it really helps them in their process.”

Proven to be a strong foundation in showcasing Biocut’s abilities, the various presses tailored to meet different clients’ pain points helped establish trust in the niche marketspace.

However, for Biocut, it was not enough to succeed in their niche of dies or presses. Their drive is deeply rooted in expansion to improve the pain points of as many clients as possible. Being trusted to successfully alleviate pain points, even in seemingly new territories is not something Biocut employees take lightly.

“We went from a spot where we didn’t really have the resources, but we always found a way to make it work. Now we’re confident that we have the resources to take on almost any product that a customer brings to us and we innovate with them,” said Koch. “So we really haven’t ever turned down a project.”

Another key component in product innovation has been ensuring customer satisfaction from beginning to end. Sometimes incorporating new technologies into processes can be overwhelming or confusing for clients, especially if it’s a machine they’ve never used before. To combat that discomfort, Biocut goes the extra mile to get clients accustomed to their new products.

SterilCut® 7T

“We really stand behind our products. If they have a problem, we have engineers on the phone with them within minutes to help them out. We’ll get on a plane the next day if we need to, to make sure that product is working for them for their solution within the process.”

Koch joined the Biocut team in 2017 as lead engineer and has since moved on from managing individual projects to overseeing the development of innovative products.

“I backed out of a lot of the detail engineering. We now have a very diverse team that can handle that, and then I’ve managed the overall product evolution and what we consider the innovation funnel.”

This diverse team includes biomedical, mechanical and manufacturing engineers to not only ensure support throughout the product’s entire life cycle, but to also increase innovation across various areas in regenerative medicine and eventually other industries.

“We’re going to continue to look for new technologies that we can implement, but then we’re going to look into some parallel markets that we can begin working in as well…We’re really excited to take on new opportunities and challenges,” said Koch.

These new challenges include the pharmaceutical market as well as ortho tools that assist in surgeries. But not to worry, the Biocut team still plans on remaining a loyal partner in the regenerative medicine sphere.

“We’re going to continue to support the regenerative medicine market space because that really gave us our start,” said Koch.